Braveheart Bio, Inc. Net Fee Amt
Braveheart Bio, Inc. (BRVE) had Net Fee Amt of $32.30 thousand as of 2026-08-06, per its S-8 filed 2026-08-06.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-06
- 2026-08-06: Net Fee Amt $32.30K.
- 2026-08-05: Net Fee Amt $7.15K.
- 2026-07-29: Net Fee Amt $36.81K.
- 2026-06-18: Net Fee Amt $13.81K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-06 | $32.30K S-8 · filed 2026-08-06 |
| 2026-08-05 | $7.15K S-1MEF · filed 2026-08-05 |
| 2026-07-29 | $36.81K S-1/A · filed 2026-07-30 |
| 2026-06-18 | $13.81K S-1 · filed 2026-07-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |